12.96
price down icon3.43%   -0.46
pre-market  Pre-market:  12.70   -0.26   -2.01%
loading
Evolus Inc stock is traded at $12.96, with a volume of 531.65K. It is down -3.43% in the last 24 hours and down -13.83% over the past month. Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
See More
Previous Close:
$13.42
Open:
$13.27
24h Volume:
531.65K
Relative Volume:
0.73
Market Cap:
$824.08M
Revenue:
$202.09M
Net Income/Loss:
$-61.69M
P/E Ratio:
-12.00
EPS:
-1.08
Net Cash Flow:
$-35.64M
1W Performance:
-4.00%
1M Performance:
-13.83%
6M Performance:
-25.90%
1Y Performance:
-7.69%
1-Day Range:
Value
$12.71
$13.41
1-Week Range:
Value
$11.93
$13.81
52-Week Range:
Value
$9.25
$17.82

Evolus Inc Stock (EOLS) Company Profile

Name
Name
Evolus Inc
Name
Phone
(949) 284-4555
Name
Address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Name
Employee
332
Name
Next Earnings Date
2025-03-04
Name
Latest SEC Filings
Name
EOLS's Discussions on Twitter

Compare EOLS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
EOLS
Evolus Inc
12.96 824.08M 202.09M -61.69M -35.64M -1.08
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
160.06 71.67B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.03 47.44B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.19 46.08B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.46 18.86B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
ITCI
Intra Cellular Therapies Inc
131.36 13.97B 612.78M -86.37M -62.91M -0.87

Evolus Inc Stock (EOLS) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-29-24 Upgrade Barclays Equal Weight → Overweight
Jun-23-22 Initiated Needham Buy
May-12-22 Upgrade Barclays Underweight → Equal Weight
Jan-20-22 Upgrade Truist Hold → Buy
May-06-21 Upgrade Mizuho Neutral → Buy
Apr-08-21 Reiterated H.C. Wainwright Buy
Feb-24-21 Downgrade Truist Buy → Hold
Jul-07-20 Downgrade Mizuho Buy → Neutral
Feb-06-20 Resumed Mizuho Buy
Nov-26-19 Initiated SVB Leerink Outperform
Sep-05-19 Resumed Mizuho Buy
Jun-28-19 Initiated Wells Fargo Market Perform
Jun-11-19 Initiated Barclays Underweight
Mar-20-19 Initiated SunTrust Buy
Feb-14-19 Initiated H.C. Wainwright Buy
Jan-29-19 Initiated Stifel Buy
View All

Evolus Inc Stock (EOLS) Latest News

pulisher
Mar 12, 2025

Evolus’s SWOT analysis: fda approval boosts stock as dermal filler market expands By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 12, 2025

Evolus’s SWOT analysis: fda approval boosts stock as dermal filler market expands - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

Evolus at Barclays Conference: Strategic Growth and New Launch - Investing.com

Mar 12, 2025
pulisher
Mar 11, 2025

Evolus at Leerink’s Global Healthcare Conference: Strategic Growth Insights - Investing.com India

Mar 11, 2025
pulisher
Mar 11, 2025

Evolus at Leerink’s Global Healthcare Conference: Strategic Growth Insights By Investing.com - Investing.com Canada

Mar 11, 2025
pulisher
Mar 10, 2025

Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas - The Motley Fool

Mar 10, 2025
pulisher
Mar 10, 2025

What is HC Wainwright’s Estimate for Evolus FY2025 Earnings? - Defense World

Mar 10, 2025
pulisher
Mar 09, 2025

(EOLS) Investment Analysis - Stock Traders Daily

Mar 09, 2025
pulisher
Mar 09, 2025

Evolus, Inc.: Navigating Financial Challenges Amidst Ongoing Losses and Market Uncertainty - MSN

Mar 09, 2025
pulisher
Mar 08, 2025

Global Jeuveau Market Outlook 2025-2034: Growth Drivers, Share, And Trends - EIN News

Mar 08, 2025
pulisher
Mar 08, 2025

Evolus, Inc. (NASDAQ:EOLS) Shares Acquired by Principal Financial Group Inc. - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

Evolus, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 07, 2025

Evolus, Inc. (NASDAQ:EOLS) Shares Acquired by Rhumbline Advisers - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

IFP Advisors Inc Has $52,000 Position in Evolus, Inc. (NASDAQ:EOLS) - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

Evolus’s Strong Market Position and Growth Potential Highlighted by Robust Revenues and Strategic Expansions - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

HC Wainwright Reaffirms “Buy” Rating for Evolus (NASDAQ:EOLS) - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

Evolus’s Promising Growth and Strategic Positioning Earns a ‘Buy’ Rating from Analyst Douglas Tsao - TipRanks

Mar 06, 2025
pulisher
Mar 05, 2025

Evolus, Inc. Earnings Call Highlights Robust Growth and Profitability - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

Evolus Inc Reports Q4 2024 Revenue of $79 Million, Surpassing Es - GuruFocus.com

Mar 05, 2025
pulisher
Mar 05, 2025

Stifel maintains Buy on Evolus stock, sets $25 target By Investing.com - Investing.com UK

Mar 05, 2025
pulisher
Mar 05, 2025

H.C. Wainwright maintains Buy rating on Evolus stock at $27 target By Investing.com - Investing.com South Africa

Mar 05, 2025
pulisher
Mar 05, 2025

H.C. Wainwright maintains Buy rating on Evolus stock at $27 target - Investing.com

Mar 05, 2025
pulisher
Mar 05, 2025

Evolus Celebrates Strong Demand For Jeuveau Wrinkle Treatment - Finimize

Mar 05, 2025
pulisher
Mar 05, 2025

Assessing Evolus: Insights From 6 Financial Analysts - Benzinga

Mar 05, 2025
pulisher
Mar 05, 2025

Evolus price target raised to $25 from $22 at Barclays - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

Evolus reports Q4 EPS (11c) vs (21c) last year - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

Evolus, Inc. (NASDAQ:EOLS) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 05, 2025
pulisher
Mar 05, 2025

Evolus Inc (EOLS) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Market ... - Yahoo Finance

Mar 05, 2025
pulisher
Mar 05, 2025

Evolus Inc (EOLS) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Market ... By GuruFocus - Investing.com Canada

Mar 05, 2025
pulisher
Mar 04, 2025

Evolus, Inc. Achieves Record Financial Growth in 2024 - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Evolus Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 04, 2025
pulisher
Mar 04, 2025

Evolus earnings missed by $0.13, revenue topped estimates - Investing.com Canada

Mar 04, 2025
pulisher
Mar 04, 2025

EVOLUS Earnings Results: $EOLS Reports Quarterly Earnings - Nasdaq

Mar 04, 2025
pulisher
Mar 04, 2025

Evolus Q4 Net Loss Narrows, Revenue Rises; Issues Guidance -March 04, 2025 at 05:42 pm EST - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Evolus, Inc. (EOLS) Q4 Earnings and Revenues Lag Estimates - Yahoo Finance

Mar 04, 2025
pulisher
Mar 04, 2025

Evolus stock rises as Q4 revenue beats estimates, 2025 outlook strong - Investing.com Australia

Mar 04, 2025
pulisher
Mar 04, 2025

Evolus stock rises as Q4 revenue beats estimates, 2025 outlook strong By Investing.com - Investing.com South Africa

Mar 04, 2025
pulisher
Mar 04, 2025

Evolus, Inc. SEC 10-K Report - TradingView

Mar 04, 2025
pulisher
Mar 04, 2025

Earnings Flash (EOLS) EVOLUS Reports Q4 Revenue $78.9M, vs. FactSet Est of $79M - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Evolus posts quarterly profit on strong sales of cosmetic injection -March 04, 2025 at 04:05 pm EST - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Evolus posts quarterly profit on strong sales of cosmetic injection - TradingView

Mar 04, 2025
pulisher
Mar 02, 2025

Is Evolus, Inc. (EOLS) the Best Small Cap Pharma Stock to Buy Now? - MSN

Mar 02, 2025
pulisher
Mar 02, 2025

EVOLUS Earnings Preview: Recent $EOLS Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 02, 2025
pulisher
Mar 02, 2025

Evolus (EOLS) to Release Earnings on Tuesday - Defense World

Mar 02, 2025
pulisher
Feb 27, 2025

Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences - Business Wire

Feb 27, 2025
pulisher
Feb 27, 2025

How To Trade (EOLS) - Stock Traders Daily

Feb 27, 2025
pulisher
Feb 27, 2025

Evolus Management to Reveal Strategic Insights at Two Major Healthcare Investor Conferences - StockTitan

Feb 27, 2025
pulisher
Feb 20, 2025

Rice Hall James & Associates LLC Acquires 43,381 Shares of Evolus, Inc. (NASDAQ:EOLS) - MarketBeat

Feb 20, 2025
pulisher
Feb 20, 2025

Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit - BioSpace

Feb 20, 2025
pulisher
Feb 20, 2025

Inside Evolus's Growth Strategy: CEO Takes Center Stage at Elite Beauty Summit - StockTitan

Feb 20, 2025
pulisher
Feb 19, 2025

Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025 - BioSpace

Feb 19, 2025

Evolus Inc Stock (EOLS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$10.31
price down icon 0.77%
$33.62
price up icon 0.63%
$99.29
price down icon 1.55%
$8.98
price down icon 2.81%
$108.99
price down icon 0.07%
$131.36
price up icon 0.08%
Cap:     |  Volume (24h):